Sunday, 22 April 2018 - 0:07
  • it
  • de
  • en
  • fr

Sandoz

Novartis starts divesting Sandoz’s North-American business ($1.6bn)

Reuters yesterday announced that Switzerland-based Novartis has started the process to divest the North-American division of Sandoz, its generic pills business. The divestiture may attract other drugmakers and private equities, ready to offer a minimum of $1.6bn, that is 8x…

Joe Jiménez, Novartis outgoing CEO, describes group’s strategy

The German daily Neue Zürcher Zeitung has published a long interview to Joe Jiménez, outgoing CEO of Switzerland-based pharmaceutical group Novartis. The American manager has addressed the ethical value of drug manufacturing and marketing and the need to make them…

Sandoz (Novartis) and Biocon announce cooperation agreement over biosimilars

Sandoz–subsidiary of Novartis’–and India-based Biocon have announced a cooperation agreement aimed at manufacturing and marketing new biosimilars for immunology and oncology. Under the terms of the agreement, Sandoz will obtain commercialization rights to novel biosimilars for NAFTA and most of…

Novartis exploring sale of part of Sandoz USA ($2-3bn)

Novartis is allegedly planning to divest part of Sandoz’s US assets for a total of approximately $2-3bn. The businesses on sale reportedly include the dermatology unit, with a minimum estimated value of $1.5bn, plus other assets with products that the…

A detailed analysis of the biosimilars market

The Basel-based daily Neue Zürcher Zeitung has published a long article about the biosimilars market and its dynamics. Biotech companies are developing at a rate with few equals and delivered revenues of approximately $100bn in the US in 2017, which…

Amazon negotiates with generics giants Mylan and Sandoz

Rumors on Amazon’s possible debut in the pharma industry are increasing. CNBC has reported that Amazon is negotiating with generics giants Mylan and Sandoz. Mylan’s shares have risen over 3% as the news have started circulating. (Source: CNBC)

Novartis hires bank to assess sale of part of Sandoz

Novartis has hired Centerview bank to review strategic options for Sandoz dermatology business. Sandoz is Novartis’ unit focusing on generics, and is under huge pressure due to the price war being fought in the rich US market. For the same…